A multicentre, randomised, open-label, Phase III trial of afatinib* versus erlotinib, as second-line treatment following first-line platinum-based chemotherapy in patients with advanced squamous cell carcinoma of the lung.
*In the EU, Taiwan and Mexico, afatinib is approved under the brand name GIOTRIF^®, and in the U.S. under the brand name GILOTRIF^® for use in patients with distinct types of NSCLC. Afatinib is under regulatory review by health authorities in Asia and other countries.